{"abstract":"The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Phyxius Therapeutics, Inc., a start-up company incorporated as a C corporation under the laws of the state of Delaware, to practice the inventions covered by the patent estate listed in the Supplementary Information section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/08/10/2021-17011.html","cfr_references":[],"citation":"86 FR 43670","comment_url":null,"comments_close_on":"2021-08-25","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 25, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-17011","effective_on":null,"end_page":43671,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/08/10/2021-17011.xml","html_url":"https://www.federalregister.gov/documents/2021/08/10/2021-17011/prospective-grant-of-an-exclusive-patent-license-multi-domain-amphipathic-helical-peptide-for-use-as","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-17011?publication_date=2021-08-10","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-08-10/2021-17011/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":464,"last_updated":"2026-07-25 22:15:03 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-08-10/pdf/2021-17011.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-17011.pdf?1628513127","publication_date":"2021-08-10","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/08/10/2021-17011.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T22:26:44Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":43670,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Multi-Domain Amphipathic Helical Peptide for Use as A Human Therapeutic in Patients With Atherosclerotic Cardiovascular Disease, Including Patients Undergoing Cardiovascular Surgery Who Are at risk of Acute Kidney Injury","toc_doc":"Multi-domain Amphipathic Helical Peptide for Use as a Human Therapeutic in Patients with Atherosclerotic Cardiovascular Disease, etc.","toc_subject":"Prospective Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}